Signs that NeuralMed ‘s operations were in serious trouble emerged in June 2025. At that time, the startup reached the lowest point in its history, which began in 2018, with monthly recurring revenue below R$100,000 and a portfolio of only eight clients.
These indicators did not align with the healthtech company ‘s thesis, whose pitch, based on the use of artificial intelligence to bring efficiency to the healthcare chain, had attracted US$7.7 million from names such as Grupo Notre Dame Intermédica, the Inter-American Development Bank, Kortex Ventures, and GK Ventures.
“We were creating very valuable technologies, but they were just technologies. And not products focused on what a company needs to do, which is results,” says Anthony Eigier , co-founder and CEO of NeuralMed, to NeoFeed . “So, we sat down, did a complete reset, and recreated the company.”
After nine months of gestation, the fruit of this project is officially being born now. NeuralMed is being renamed level. And, in addition to Eigier and André Castilla, the founders of the former operation, the new company also has Mariana Gaspers as a founding partner.
With experience as CFO and CRO at companies like Twilio, Hilab, and Ascential, Gaspers joined NeuralMed in September 2024. And his arrival was one of the driving forces behind this change in logo and positioning.
“I came with a strong go-to-market mindset and wanted to help people understand the power of what we had at hand,” she says. “But it was necessary to transform that into a less tech-oriented and more business-oriented language.”
Eigier says that, until then, the startup talked a lot about computer vision. But he understood that it was necessary to overcome the taboos of the healthcare market and talk about what really mattered: at the end of the day, any client, from a hospital to a clinic, wants to increase revenue or reduce costs.
“We had a very geeky mindset, wanting to do everything,” says Eigier. “We managed to understand that 2% of all patients are the ones who generate revenue for our clients. And we directed all our messaging towards that.”
In addition to structuring sales teams, the company added other elements to this conversation. Among them was the promise not to receive a single cent if the promised targets were not met within the timeframe agreed upon by both parties.
“This completely changed the speed of sales,” says Gaspers. “Because customers stopped seeing us as just another hyped artificial intelligence solution on the market.”
In numerical terms, the healthtech company went from a previous average of over 180 days to finalize a sale to the current rate of 30 to 60 days. At the implementation stage of its tools, the timeframe is now between 45 and 60 days, compared to 6 months to a year before this turnaround.
This faster rollout also involved repackaging the offerings, delivered in a software-as-a-service model. From a series of previously scattered solutions, they were consolidated into two packages, named Light, with access to fewer features, and Full.
The underlying principle behind the applications, however, has not changed. In short, the platform acts as an intelligence layer that connects the most diverse systems and data of clients – from electronic medical records to reports and prescriptions.
Among other resources, by cross-referencing this data with a battery of AI algorithms, it is possible to anticipate diagnoses and point out potential risks for patients that were not identified by medical teams, for example, in a specific examination performed for another purpose.
“Our algorithms already perform these analyses 350 times faster than a human being, and we are approaching 500 times,” says Eigier. “That’s the great power of AI. To achieve that, you would need 400 highly trained nurses who never tire, never get distracted, and just work all the time.”
The platform covers areas such as oncology and diseases like asthma, diabetes, and hypertension. It has also been enhanced with features like WhatsApp chatbots, which connect with patients, whether to schedule an appointment or alert them about the need for a specific test.
“The dream of 100% of healthtech companies”
During this transition, the startup also reached another type of client: pharmaceutical companies. The argument? An early diagnosis of cancer, for example, allows these companies to participate in the treatment from the beginning, increasing the chance of patient survival and, at the same time, boosting their sales.
“Pharmaceutical companies have always been the richest segment of this story and the dream of 100% of healthtech companies,” says Eigier. “We had been negotiating for years and managed to unlock this in recent months.” The first contracts involved Adium, from Uruguay, and a European company, whose name was not revealed.
Other names have joined this rebranding. From 8 clients, just over 9 months ago, Level is born with a portfolio of 36 companies. The list includes institutions such as the Moinhos de Vento and Mãe de Deus hospitals, in Porto Alegre (RS), as well as the Santa Casa, also in the capital of Rio Grande do Sul.
Following this path, from an annual recurring revenue (ARR) of less than R$1.2 million, the company has jumped to a current base of R$5 million. And it has already contracted an additional volume of R$10 million, with projections to boost this number by the end of 2026.
“We needed to be honest and let go of the burden of the past to truly begin a new story,” says Eigier. “And these last few months have proven that this thesis makes sense, both in terms of clients and revenue. And that we are, in fact, a new company.”
